Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis

详细信息    查看全文

• 作者：Christian Rupp ; Konrad Alexander Bode ; Fadi Chahoud…
• 关键词：Primary sclerosing cholangitis ; Candida ; Fungobilia ; Biliary infection ; Dominant stenosis ; Liver transplantation ; Cholestatic liver disease ; Cholangiocarcinoma
• 刊名：BMC Infectious Diseases
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：400 KB
• 参考文献：1. Hirschfield, GM, Karlsen, TH, Lindor, KD, Adams, DH (2013) Primary sclerosing cholangitis. Lancet 382: pp. 1587-1599 CrossRef
  2. Chapman, R, Fevery, J, Kalloo, A, Nagorney, DM, Boberg, KM, Shneider, B, Gores, GJ (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology 51: pp. 660-678 CrossRef
  3. Eaton, JE, Talwalkar, JA, Lazaridis, KN, Gores, GJ, Lindor, KD (2013) Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145: pp. 521-536 CrossRef
  4. Karlsen, TH, Boberg, KM (2013) Update on primary sclerosing cholangitis. J Hepatol 59: pp. 571-582 CrossRef
  5. Imam, MH, Sinakos, E, Gossard, AA, Kowdley, KV, Luketic, VA, Edwyn Harrison, M, McCashland, T, Befeler, AS, Harnois, D, Jorgensen, R, Petz, J, Keach, J, DeCook, AC, Enders, F, Lindor, KD (2011) High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 34: pp. 1185-1192 CrossRef
  6. Lindor, KD, Kowdley, KV, Luketic, VA, Harrison, ME, McCashland, T, Befeler, AS, Harnois, D, Jorgensen, R, Petz, J, Keach, J, Mooney, J, Sargeant, C, Braaten, J, Bernard, T, King, D, Miceli, E, Schmoll, J, Hoskin, T, Thapa, P, Enders, F (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50: pp. 808-814 CrossRef
  7. Pardi, DS, Loftus, EV, Kremers, WK, Keach, J, Lindor, KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: pp. 889-893 CrossRef
  8. Beuers, U, Spengler, U, Kruis, W, Aydemir, U, Wiebecke, B, Heldwein, W, Weinzierl, M, Pape, GR, Sauerbruch, T, Paumgartner, G (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16: pp. 707-714 CrossRef
  9. Singal, AK, Guturu, P, Hmoud, B, Kuo, YF, Salameh, H, Wiesner, RH (2013) Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95: pp. 755-760 CrossRef
  10. Boonstra, K, Weersma, RK, Erpecum, KJ, Rauws, EA, Spanier, BW, Poen, AC, Nieuwkerk, KM, Drenth, JP, Witteman, BJ, Tuynman, HA, Naber, AH, Kingma, PJ, Buuren, HR, Hoek, B, Vleggaar, FP, Geloven, N, Beuers, U, Ponsioen, CY (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58: pp. 2045-2055 CrossRef
  11. Karlsen, TH, Franke, A, Melum, E, Kaser, A, Hov, JR, Balschun, T, Lie, BA, Bergquist, A, Schramm, C, Weismuller, TJ, Gotthardt, D, Rust, C, Philipp, EE, Fritz, T, Henckaerts, L, Weersma, RK, Stokkers, P, Ponsioen, CY, Wijmenga, C, Sterneck, M, Nothnagel, M, Hampe, J, Teufel, A, Runz, H, Rosenstiel, P, Stiehl, A, Vermeire, S, Beuers, U, Manns, MP, Schrumpf, E (2010) Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138: pp. 1102-1111 CrossRef
  12. Ellinghaus, D, Folseraas, T, Holm, K, Ellinghaus, E, Melum, E, Balschun, T, Laerdahl, JK, Shiryaev, A, Gotthardt, DN, Weismuller, TJ, Schramm, C, Wittig, M, Bergquist, A, Bjornsson, E, Marschall, HU, Vatn, M, Teufel, A, Rust, C, Gieger, C, Wichmann, HE, Runz, H, Sterneck, M, Rupp, C, Braun, F, Weersma, RK, Wijmenga, C, Ponsioen, CY, Mathew, CG, Rutgeerts, P, Vermeire, S (2013) Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 58: pp. 1074-1083 CrossRef
  13. Liu
• 刊物主题：Infectious Diseases; Parasitology; Medical Microbiology; Tropical Medicine; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2334

文摘

Background Candidiasis is commonly observed in patients with primary sclerosing cholangitis (PSC), but the clinical risk factors associated with its presence have not been fully investigated. In this study, we aimed to analyse the incidence, risk factors, and transplantation-free survival in primary sclerosing cholangitis (PSC) patients with persistent biliary candidiasis. Methods We retrospectively analysed patients diagnosed with PSC who were admitted to our department during 2002 to 2012. One-hundred fifty patients whose bile cultures were tested for fungal species were selected, and their clinical and laboratory parameters were investigated. The results of endoscopic retrograde cholangiography (ERC) and bile cultures were analysed using chart reviews. The cases of biliary candidiasis were sub-classified as transient or persistent. Results Thirty out of 150 (20.0%) patients had biliary candidiasis. Although all patients demonstrated comparable baseline characteristics, those with biliary candidiasis showed significantly reduced transplantation-free survival (p--.0001) along with a markedly elevated frequency of cholangiocarcinoma (CCA) (p--.04). The patients were further sub-classified according to the transient (15/30) or persistent (15/30) nature of their biliary candidiasis. A subgroup analysis showed reduced survival with a greater necessity for orthotopic liver transplantation (OLT) only in patients with persistence of Candida (p--.007). The survival in the patients with transient biliary candidiasis was comparable to that in candidiasis-free patients. In a multivariate regression analysis that included Mayo risk score (MRS), sex, age, dominant stenosis, inflammatory bowel disease, autoimmune hepatitis overlap syndrome, and number of times ERC was performed, biliary candidiasis was an independent risk factor for reduced survival (p--.008). Risk factors associated with acquisition of biliary candidiasis were age at PSC diagnosis and number of ERCs. Conclusions The persistence of biliary candidiasis is associated with markedly reduced transplantation-free survival in PSC patients. By contrast, actuarial survival in patients with transient biliary candidiasis approaches that for patients without any evidence of biliary candidiasis. Further studies on the treatment of persistent biliary candidiasis in patients with PSC are warranted.